Plasma Versus Whole Blood Tacrolimus Concentrations and Health-Related Quality of Life in Kidney Transplant Recipients
Pharmaceutics · 30.04.2025 · 17 (5) · 590
DOI: 10.3390/pharmaceutics17050590 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 30.04.2025. Verfasst von Svea Nolte und 14 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherl…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Astellas Pharma (Netherlands), Chiesi Pharmaceuticals BV, Dutch Ministry of Economic Affairs and Climate Policy.
Abstract (Originalsprache)
Background/Objectives: Tacrolimus dosing traditionally relies on therapeutic drug monitoring in whole blood, while assessment in plasma may better reflect its effect and reveal overdosing impacting health-related quality of life (HRQoL).
Methods
In this cross-sectional study, 898 kidney transplant recipients (KTRs) who were at least 12 months post-transplantation were included. Plasma and whole blood tacrolimus concentrations were compared using Passing–Bablok regression analyses and Bland–Altman plots. Furthermore, the relationship with daily tacrolimus dose and with HRQoL (mental component summary (MCS), physical component summary (PCS)) was explored using linear regression by comparing standardized coefficients. Lastly, mediation analyses explored the effect of various tacrolimus-related side effects on the association between tacrolimus concentrations and HRQoL.
Results
Comparison of the methods revealed a constant bias and a slight proportional bias between whole blood and plasma tacrolimus concentrations. The Bland–Altman plots indicated poor agreement with a statistically significant ratio difference (p < 0.001). Both whole blood and plasma concentrations were significantly associated with daily tacrolimus dose (both p < 0.001). Compared to whole blood tacrolimus concentrations, plasma tacrolimus concentration showed a strong negative association with worse HRQoL (PCS: st. β = −0.12, p = 0.01; MCS: st. β = −0.14, p < 0.001). The associations between plasma tacrolimus concentrations and HRQoL were mediated by fatigue severity (proportion mediated on PCS: 67.8%, MCS: 59.5%) and reduced kidney function (proportion mediated on PCS: 16.7%, MCS: 12.9%).
Conclusions
In conclusion, compared with whole blood tacrolimus concentrations, plasma tacrolimus concentrations exhibited a negative association with HRQoL in KTRs. Consequently, therapeutic drug monitoring using plasma tacrolimus concentrations may reduce the occurrence of tacrolimus-related toxicity.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
- Department of Neurology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
- Department of Gastroenterology and Hepatology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
- Department of Epidemiology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
- Department of Clinical Pharmacy and Pharmacology, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
- Department of Neurosurgery, University Medical Center Groningen, University of Groningen, 9713 GZ Groningen, The Netherlands.
ORCID-Profile: Svea Nolte, J Casper Swarte, Tim J Knobbe, Ilja M Nolte, Tanja R Zijp, Marco van Londen, Niels L Riemersma, Johannes R Björk, Gea Drost, Stefan P Berger, Daan J Touw, Stephan J L Bakker
Förderung
- Astellas Pharma (Netherlands)
- Chiesi Pharmaceuticals BV
- Dutch Ministry of Economic Affairs and Climate Policy
- Astellas BV
- NWO/TTW via a partnership program with DSM, Animal Nutrition and Health, The Netherlands
Zitieren
APA
Nolte, S., Swarte, J. C., Knobbe, T. J., Nolte, I. M., Zijp, T. R., Moes, H. R., van Londen, M., Riemersma, N. L., Björk, J. R., Weersma, R. K., Drost, G., Berger, S. P., Touw, D. J., Bakker, S. J. L., & TransplantLines Investigators (2025). Plasma Versus Whole Blood Tacrolimus Concentrations and Health-Related Quality of Life in Kidney Transplant Recipients. Pharmaceutics, 17(5), 590. https://doi.org/10.3390/pharmaceutics17050590
Vancouver
Nolte S, Swarte JC, Knobbe TJ, Nolte IM, Zijp TR, Moes HR, et al. Plasma Versus Whole Blood Tacrolimus Concentrations and Health-Related Quality of Life in Kidney Transplant Recipients. Pharmaceutics. 2025;17(5):590. doi:10.3390/pharmaceutics17050590
BibTeX
@article{Nolte2025,
author = {Nolte, Svea and Swarte, J Casper and Knobbe, Tim J and Nolte, Ilja M and Zijp, Tanja R and Moes, Harmen R and van Londen, Marco and Riemersma, Niels L and Björk, Johannes R and Weersma, Rinse K and Drost, Gea and Berger, Stefan P and Touw, Daan J and Bakker, Stephan J L and TransplantLines Investigators, TransplantLines Investigators},
title = {Plasma Versus Whole Blood Tacrolimus Concentrations and Health-Related Quality of Life in Kidney Transplant Recipients},
journal = {Pharmaceutics},
year = {2025},
volume = {17},
number = {5},
pages = {590},
doi = {10.3390/pharmaceutics17050590}
}
EUVIMED